Surgical Bleeding Clinical Trial
Official title:
Prospective, Randomized, Controlled, Multicenter, Clinical Investigation Evaluating the Safety of HEMOBLAST™ Bellows in Spine Surgery
| Verified date | April 2024 |
| Source | Dilon Technologies Inc. |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
The purpose of this clinical investigation in open, elective, spine surgery is to collect data to support the removal of the neurosurgical exclusion from the currently approved indication for the use of HEMOBLAST™ Bellows. This study is primarily designed to assess safety of the device for use in spine surgery, although efficacy information will also be captured and reported.
| Status | Completed |
| Enrollment | 60 |
| Est. completion date | February 5, 2024 |
| Est. primary completion date | February 5, 2024 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 22 Years and older |
| Eligibility | Inclusion Criteria: - Subject is undergoing open, elective, spine surgery - Subject or an authorized legal representative is willing and able to give prior written informed consent for investigation participation - Subject is 22 years of age or older - Subject does not have an active or suspected infection at the surgical site - Subject in whom the Investigator is able to identify a Target Bleeding Site (TBS) for which any applicable conventional means for hemostasis are ineffective or impractical - Subject has a TBS with a Surface Bleeding Severity Scale (SBSS) score of 1, 2, or 3 Exclusion Criteria: - Subject is undergoing an emergency surgical procedure - Subject is undergoing a laparoscopic surgery - Subject is undergoing a cervical spine surgery - Subject is pregnant, planning on becoming pregnant during the follow-up period, or actively breast-feeding - Subject has a platelet count < 100,000 per microliter or International Normalized Ratio > 1.5 within 4 weeks of surgery - Subject receiving intravenous heparin within 12 hours before surgery or oral Coumadin within 2 days before surgery - Subject receiving antiplatelet medications within 5 days prior to surgery - Subject receiving aspirin within 7 days prior to surgery - Subject has an active or suspected infection at the surgical site - Subject has had or has planned to receive any organ transplantation - Subject has a known sensitivity or allergy to bovine and/or porcine substance(s) or any other component(s) of the hemostatic agent - Subject has a known sensitivity or allergy to Gadolinium - The subject has a contra-indication for MRI or gadolinium contrast agent according to clinical guidelines, local regulations or manufacturer's recommendations - Subject suffers from claustrophobia or fear of MRI, or has any contraindication to MRI (e.g., metal implants, spinal cord stimulator, etc. not suited to MRI) - Subject has American Society of Anesthesiologists classification of > 4 - Subject has a life expectancy of less than 3 months - Subject has a documented severe congenital or acquired immunodeficiency - Subject has religious or other objections to porcine, bovine, or human components - Subject is currently participating or has participated in another clinical trial within the past 30 days and is receiving/has received an investigational drug, device, or biologic agent - Per investigator opinion subject is unable to fully cooperate with the study protocol. - The product will be placed in at the site where the dura is open - The product will be placed in the intradural or cranial space |
| Country | Name | City | State |
|---|---|---|---|
| United States | Johns Hopkins Bayview Medical Center | Baltimore | Maryland |
| United States | Massachusetts General Hospital | Boston | Massachusetts |
| United States | Indiana Spine Group | Carmel | Indiana |
| United States | Spectrum Medical Inc | Danville | Virginia |
| United States | University of Southern California | Los Angeles | California |
| Lead Sponsor | Collaborator |
|---|---|
| Dilon Technologies Inc. | Syneos Health |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Other | Hemostasis within 6 minutes | Proportion of subjects achieving hemostasis within 6 minutes for HEMOBLAST™ subjects compared to G+T subjects | immediately after procedure | |
| Other | Operative time | Operative time for HEMOBLAST™ subjects compared to G+T subjects | immediately after procedure | |
| Other | Length of stay | Duration of hospitalization for HEMOBLAST™ subjects compared to G+T subjects | From procedure to discharge, estimated average = 36 hours | |
| Other | Blood transfusions | Number of units of blood transfused intraoperatively for HEMOBLAST™ subjects compared to G+T subjects | From procedure to discharge, estimated average = 36 hours | |
| Primary | Incidence of Unanticipated Adverse Device Effect (UADE) | incidence of UADE, for subjects treated with HEMOBLAST™, as determined by the Independent Data Monitoring Committee (IDMC). | 3 months follow-up | |
| Secondary | Adverse events (AE) | the proportion of AEs for subjects treated with HEMOBLAST™ compared to subjects treated with G+T. | 3 months follow-up |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02284256 -
A Safety and Efficacy Study Comparing Fibrocaps and Tachosil in Hepatic Surgery
|
Phase 3 | |
| Completed |
NCT01653769 -
CoSeal for Hemostasis of Aortic Anastamoses
|
N/A | |
| Terminated |
NCT02117349 -
Topical Raplixa for Surgical Bleeding in Children
|
Phase 2 |